ReviewPharmacy (Basel, Switzerland)2019
Sulfonamide Allergies.
Review in Pharmacy (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 79 citations in OpenAlex.
- Ιdiosyncratic Non-Cardiogenic Pulmonary Edema Following Acetazolamide Administration: A Case Report and Review of Pathogenic Mechanisms.Reports (MDPI) · 2026Article
- Design and Synthesis of DyMolecules (Basel, Switzerland) · 2025Article
- Prescribing carbonic anhydrase inhibitors to patients with "sulfa" antibiotics allergy: do we dare?Eye (London, England) · 2025Article
- Impact of sulfonamide allergy label on clinical outcomes of acute cystitis: a retrospective matched cohort study.Internal medicine journal · 2025Article
- Cefiderocol for the Treatment of Nosocomial Bloodstream Infections Caused by Stenotrophomonas maltophilia: A Case Series and Literature Review.Infectious diseases and therapy · 2025Article
- Article
- Probenecid as a pharmacotherapy for alcohol use disorder: A randomized placebo-controlled alcohol interaction trial.Alcohol, clinical & experimental research · 2024Article
- Unveiling sultam in drug discovery: spotlight on the underexplored scaffold.RSC medicinal chemistry · 2024Review
- Impact of Sulfonamide Allergy Label on Clinical Outcomes in Patients with Pneumocystis jirovecii Pneumonia.Pulmonary therapy · 2024Article
- Analysis of Allergy and Hypersensitivity Reactions to COVID-19 Vaccines According to the EudraVigilance Database.Life (Basel, Switzerland) · 2024Article
- How to Define and Manage Low-Risk Drug Allergy Labels.The journal of allergy and clinical immunology. In practice · 2024Review
- Article
- Antibiotic prophylaxis in immunosuppressed patients - Missed opportunities from trimethoprim-sulfamethoxazole allergy label.The World Allergy Organization journal · 2024Review
- A Comprehensive Review of Sulfonamide Hypersensitivity: Implications for Clinical Practice.Clinical reviews in allergy & immunology · 2023Review
- ROCK Inhibitors in Corneal Diseases and Glaucoma-A Comprehensive Review of These Emerging Drugs.Journal of clinical medicine · 2023Review
- Management and Mitigation of Vibriosis in Aquaculture: Nanoparticles as Promising Alternatives.International journal of molecular sciences · 2023Review
- Feasibility of trimethoprim/sulfamethoxazole desensitization therapy in hematological diseases.Clinical and experimental medicine · 2023Article
- Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race.International journal of molecular sciences · 2023Review
- The role of unconventional T cells in maintaining tissue homeostasis.Seminars in immunology · 2022Review
- Antibiotic Prescribing Patterns and Guideline Concordance for Uncomplicated Urinary Tract Infections Among Adult Women in the US Military Health System.JAMA network open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As one of the earliest developed antimicrobial classes, sulfonamides remain important therapeutic options for the empiric and definitive treatment of various infectious diseases. In the general population, approximately 3-8% of patients are reported to experience a sulfonamide allergy. Sulfonamide allergies can result in various physical manifestations; however, rash is reported as the most frequently observed. In patients with human immunodeficiency virus (HIV), dermatologic reactions to sulfonamide antimicrobial agents occur 10 to 20 times more frequently compared to immunocompetent patients. This article describes the incidence, manifestations, and risk factors associated with sulfonamide allergies. The potential for cross-reactivity of allergies to sulfonamide antimicrobials with nonantimicrobial sulfonamide medications is also reviewed. Data suggest that substitutions at the N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.